Analysts See Domestic Formulations, US Shortage Driving Growth

Sun Pharmaceuticals Industries is expected to deliver strong growth in both the US and domestic markets, driven by its specialty portfolio, according to Centrum Broking.

Dr. Reddy’s is anticipated to benefit from its strong domestic presence and the continued contribution of its gRevlimid sales,…